Inogen Announces the Appointment of Andy Reding as Chief Operating Officer
BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen Announces the Appointment of Andy Reding as Chief Operating Officer.
Business Wire7/1/2026Neutral
INGN
Inogen IncNASDAQHEALTHCAREMEDICAL DEVICES
Key Statistics
Market Cap
$175.71M
P/E Ratio
—
EPS
$-0.91
Beta
1.59
52W High
$9.13
52W Low
$5.34
50-Day MA
$6.61
200-Day MA
$6.83
Dividend Yield
—
Profit Margin
-7.08%
Forward P/E
—
PEG Ratio
3.48
About Inogen Inc
Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other physicians, and third-party payers in the United States and internationally. The company is headquartered in Goleta, California.
Fundamentals
| Revenue (TTM) | $351.50M |
| Gross Profit (TTM) | $155.76M |
| EBITDA | $-8.81M |
| Operating Margin | -9.89% |
| Return on Equity | -13.10% |
| Return on Assets | -6.14% |
| Revenue/Share (TTM) | $12.95 |
| Book Value | $6.68 |
| Price-to-Book | 0.98 |
| Price-to-Sales (TTM) | 0.50 |
| EV/Revenue | 0.243 |
| EV/EBITDA | -17.60 |
| Quarterly Earnings Growth (YoY) | 87.30% |
| Quarterly Revenue Growth (YoY) | 3.40% |
| Shares Outstanding | $27.07M |
| Float | $23.67M |
| % Insiders | 12.64% |
| % Institutions | 77.28% |
Historical Volatility
HV 10-Day
48.33%
HV 20-Day
43.81%
HV 30-Day
47.74%
HV 60-Day
45.22%
HV Rank
69.8%
Volatility is currently expanding
Analyst Ratings
Consensus ($12.67 target)
1
Strong Buy2
BuyLatest News
Here's Why You Should Retain Inogen Stock in Your Portfolio for Now
INGN's POC strength, expanding respiratory portfolio and international momentum support growth, though U.S. revenue pressure remains a key risk.
Zacks Investment Research6/25/2026Positive
Here's Why You Should Retain Inogen Stock in Your Portfolio for Now
INGN broadens beyond portable oxygen concentrators into home respiratory care, but U.S. revenues face pressure from channel shifts.
Zacks Investment Research5/22/2026Neutral
Inogen, Inc. (INGN) Q1 2026 Earnings Call Transcript
Inogen, Inc. (INGN) Q1 2026 Earnings Call Transcript
Seeking Alpha5/8/2026Neutral
INGN Stock Dips on Q1 Earnings Miss, Sales Up Y/Y, Gross Margin Improves
Inogen posts higher Q1 revenues and improved gross margin as international portable oxygen demand offsets weaker U.S. sales.
Zacks Investment Research5/8/2026Negative
Inogen Announces First Quarter 2026 Financial Results
BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen Announces First Quarter 2026 Financial Results.
Business Wire5/7/2026Neutral
Inogen to Report First Quarter 2026 Financial Results on May 7, 2026
BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen to Report First Quarter 2026 Financial Results on May 7, 2026.
Business Wire4/23/2026Neutral
Here's Why You Should Retain Inogen Stock in Your Portfolio for Now
INGN rides surging POC demand and global growth tailwinds, but U.S. channel shifts and macro risks may weigh on near-term performance.
Zacks Investment Research4/22/2026Positive
Inogen (INGN) Surges 6.9%: Is This an Indication of Further Gains?
Inogen (INGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks Investment Research4/8/2026Positive
More HEALTHCARE Stocks
Data last updated: 7/9/2026